Compare MOFG & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOFG | BCYC |
|---|---|---|
| Founded | 1934 | 2009 |
| Country | United States | United Kingdom |
| Employees | 757 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.6M | 438.4M |
| IPO Year | N/A | 2019 |
| Metric | MOFG | BCYC |
|---|---|---|
| Price | $41.13 | $7.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $40.50 | $18.73 |
| AVG Volume (30 Days) | 266.3K | ★ 303.3K |
| Earning Date | 01-22-2026 | 10-30-2025 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.81 | N/A |
| Revenue | ★ $221,843,000.00 | $28,339,000.00 |
| Revenue This Year | $241.79 | N/A |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | $14.62 | ★ N/A |
| Revenue Growth | ★ 504.86 | N/A |
| 52 Week Low | $24.62 | $6.03 |
| 52 Week High | $42.38 | $21.21 |
| Indicator | MOFG | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 65.53 | 55.07 |
| Support Level | $38.46 | $7.03 |
| Resistance Level | $42.38 | $7.65 |
| Average True Range (ATR) | 1.17 | 0.38 |
| MACD | -0.08 | 0.10 |
| Stochastic Oscillator | 73.88 | 73.86 |
MidWestOne Financial Group Inc is a bank holding company engaged in delivering relationship-based business and personal banking products and services. The Bank provides commercial loans, real estate loans, agricultural loans, credit card loans, and consumer loans. It also provides deposit products including demand and interest checking accounts, savings accounts, money market accounts, and time deposits. The Bank also provides products and services including treasury management, Zelle, online and mobile banking, debit cards, ATMs, and safe deposit boxes. The Bank offers its products and services through its network of full-service banking offices. the Bank's investments services department offers financial planning, investment advisory, and retail securities brokerage services.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.